Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

- PMLiVE

NICE backs Bayer’s Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

- PMLiVE

Bayer sells diabetes division to Panasonic Healthcare

€1.02bn sale includes Contour electronic meters and other medical devices

- PMLiVE

Just manufacturing pills ‘no longer good enough for patients’

Pharma must truly move beyond the pill and embrace digital health, according to industry heads

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

- PMLiVE

Bayer renews contract with Ashfield Meetings & Events

Partnership have been working together since 2012

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

- PMLiVE

J&J takes external advice on compassionate use

Drugmaker will run a pilot for a review of one late-stage project

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links